Search results
Author(s):
Kazeen Abdullah
,
Anand Rohatgi
Added:
3 years ago
Statins are currently the most efficacious and widely prescribed lipid-lowering medications.1 Numerous randomised controlled trials across a spectrum of baseline atherosclerotic cardiovascular disease (ASCVD) risk show that a 1.0 mmol/L (~40 mg/dL) reduction in low-density lipoprotein cholesterol (LDL-C) with statin therapy is associated with an overall 21 % reduction in major vascular events and…
View more
Author(s):
Stephen J Nicholls
Added:
3 years ago
Therapeutic targeting of dyslipidaemia has been one of the major successes in cardiovascular medicine over the last three decades. On the basis of unequivocal evidence from animal models through to both population and genetic studies in humans, there is a clear association between increasing levels of LDL cholesterol (LDL-C) and incident cardiovascular risk.1 This has prompted efforts to develop…
View more
Giselle Melendez
Research Area(s) / Expertise:
Job title: Assistant Professor
Author
Author(s):
Cesare Rusconi
Added:
3 years ago
With the widespread availability of non-invasive bedside assessment of ventricular function by echocardiography in the last two decades the paradigm of heart failure (HF), presumed to be usually due to an impaired left ventricular (LV) systolic function, has been challenged by the finding that about half of patients suffering from HF syndrome exhibit a normal LV ejection fraction (LVEF), and the…
View more
Author(s):
Michael Honigberg
Added:
4 months ago
AHA 23 — Dr Michael Honigberg (Massachusetts General Hospital, US) highlights key 2023 cardiology updates, featuring novel data from AHA Scientific Sessions.Dr Honigberg provides commentary on the new SELECT trial outcomes and emphasises the incretin mimetic, semaglutide's role in cardiovascular medicine. He delves into lipid management with a focus on the CLEAR trial data and the incorporation…
View more
Author(s):
Reynaria N Pitts
,
Robert Eckel
Added:
3 years ago
Elevated levels of low-density lipoprotein cholesterol (LDL-C) have long been established as one of the most important risk factors for developing coronary artery disease (CAD) and other forms of atherosclerotic cardiovascular disease (CVD).1,2 Targeting LDL-C reduction has been effective in lowering cardiovascular risk.3,4 The use of HMGCoA reductase inhibitors (statins) for both primary and…
View more
Author(s):
Julio Núñez
Added:
2 years ago
In this video interview from ESC's 2021 Heart Failure Congress, Dr Julio Nunez Villota (University of Valencia, Valencia, ES) discusses the findings of the Preserve-HR trial. This was a randomised single-center study that aimed to find the effect of beta-blocker withdrawal in patients with HFpEF and chronotropic incompetence.
Questions:
1. Could you briefly remind us of the trial's main aims,…
View more
Author(s):
Kristian Rivera
,
Cristina Marzo
,
Nuria Sans
,
et al
Added:
3 years ago
Topic: 1. Clinical Cardiology
Introduction
Universal use of Direct Oral Anticoagulants (DOACs) in non-valvular atrial fibrillation (nVAF) is not possible for economic reasons. It is necessary to prescribe them to those patients with greater potential benefit. The best way to achieve this objective is the application of a territorial protocol, designed and accepted by all professionals…
View more
Author(s):
John JV McMurray
Added:
1 year ago
ESC Congress – Prof John McMurray (University of Glasgow, UK) joined us to discuss the finding of the PERSPECTIVE trial (NCT02884206).
The trial assessed whether the angiotensin receptor-neprilysin inhibitor (ARNi), sacubitril/valsartan (Novartis) has any negative impact on cognitive function in people who have heart failure with preserved ejection fraction (HFpEF) when compared with HFpEF…
View more
Author(s):
Harald Becher
,
Robert Olszewski
Added:
3 years ago
Contrast echocardiography has become an indispensable tool in non-invasive imaging. In the last decade new contrast agents and contrast-specific imaging technologies have simplified the clinical use of contrast agents and dramatically improved the images acquired. However, there is a price to pay: extra time, the costs of the agent and a small risk of intolerance reactions. Significant…
View more